Read more

October 29, 2023
3 min watch
Save

VIDEO: Interim results promising for RGX-314 in diabetic retinopathy

SEATTLE — In this Healio Video Perspective from the ASRS meeting, Dilsher Dhoot, MD, discusses the interim results of the phase 2 ALTITUDE trial investigating three doses of RGX-314 gene therapy in diabetic retinopathy.

“If we look at dose levels one and two, we saw ‘any improvement’ in [Diabetic Retinopathy Severity Scale] of 54% in both doses combined compared to 20% improvement in the sham group,” he said.

Dhoot also discussed 6-month safety data.